Drug Trial Radar · NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,024
Actual
Start
Jan 16, 2024
Primary completion
Mar 4, 2026
Study completion Apr 6, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Conditions
- Type 2 Diabetes
Interventions
CagrilintideDrug
Cagrilintide will be administered subcutaneously.
SemaglutideDrug
Semaglutide will be administered subcutaneously.
TirzepatideDrug
Tirzepatide will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 68)
- Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
Locations
197 sites in 8 countries. Site status is shown where the registry gives one.
Synexus Clin Res-Birmingham
Birmingham, Alabama
Univ of Alabama_Birmingham
Birmingham, Alabama
Prime Medical Group, LLC
Gilbert, Arizona
Velocity Clinical Research-Phoenix
Phoenix, Arizona
Synexus Rsch /Cnt Phnx Med C
Phoenix, Arizona
Arkansas Clinical Research
Little Rock, Arkansas
Unity Health-Searcy Medical Center
Searcy, Arkansas
Velocity Clin Res-Chula Vista
Chula Vista, California
Headlands Research California, LLC
Escondido, California
Neighborhood Healthcare
Escondido, California
St. Jude Heritage Yorba Linda - Pediatric Ste D
Fullerton, California
Diabetes & Endocrine Specialists - La Mesa
La Mesa, California
Diabetes and Endocrine Specialists - La Mesa
La Mesa, California
Velocity Clin Res San Diego
La Mesa, California
Headlands Research CTR Lincoln
Lincoln, California
Loma Linda Univ Hlth Cr Endo
Loma Linda, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Healthcare
Palm Springs, California
Velocity Clin Res - Panorama
Panorama City, California
Western University of Health Sciences
Pomona, California
Endocrinology Josel Cabaccan
San Jose, California
Mills-Peninsula Medical Center
San Mateo, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Premier Medical Center, Inc.
Toluca Lake, California
Velocity Clin Res - Panorama
Van Nuys, California
Diablo Clinical Research, Inc.
Walnut Creek, California
University of Colorado Hospital
Aurora, Colorado
Optumcare Clinical Trials,LLC-Golden
Colorado Springs, Colorado
Northeast Res Inst. Inc.
Jacksonville, Florida
Bioclinical Research Alliance
Miami, Florida
New Horizon Research Center
Miami, Florida
South Broward Research LLC
Miramar, Florida
West Orange Endocrinology
Ocoee, Florida
Optimal Research Sites
Orange City, Florida
Trans Res Inst for Met & Diab
Orlando, Florida
Oviedo Medical Research, LLC
Oviedo, Florida
Center for Diab,Obes & Metab
Pembroke Pines, Florida
Hope Clin Res & Wellness
Conyers, Georgia
Center for Adv Res & Education
Gainesville, Georgia
Urban Family Practice Assoc
Marietta, Georgia
Showing 40 of 197 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.